Advanced

LTX-109 is a Novel Agent for Nasal Decolonisation of Methicillin Resistant and Sensitive Staphylococcus aureus.

Nilsson, Anna LU ; Janson, Håkan LU ; Wold, Hedda; Fugelli, Anders; Andersson, Karin; Håkangård, Camilla; Olsson, Pernilla and Olsen, Wenche Marie (2015) In Antimicrobial Agents and Chemotherapy 59(1). p.145-151
Abstract
Nasal decolonisation has a proven effect on the prevention of severe Staphylococcus aureus infections and in the control of methicillin resistant S. aureus (MRSA). However, rising rates of resistance to antibiotics highlights the need for new substances for nasal decolonisation. LTX-109 is a broad spectrum, fast-acting bactericidal antimicrobial drug for topical treatment, which causes membrane disruption and cell lysis. This mechanism of action is not associated with cross-resistance and has a low propensity for development of resistance. In the present study persistent nasal MRSA and methicillin sensitive S. aureus carriers were treated for three days with vehicle, 1%, 2% or 5% LTX-109, respectively. A significant effect on nasal... (More)
Nasal decolonisation has a proven effect on the prevention of severe Staphylococcus aureus infections and in the control of methicillin resistant S. aureus (MRSA). However, rising rates of resistance to antibiotics highlights the need for new substances for nasal decolonisation. LTX-109 is a broad spectrum, fast-acting bactericidal antimicrobial drug for topical treatment, which causes membrane disruption and cell lysis. This mechanism of action is not associated with cross-resistance and has a low propensity for development of resistance. In the present study persistent nasal MRSA and methicillin sensitive S. aureus carriers were treated for three days with vehicle, 1%, 2% or 5% LTX-109, respectively. A significant effect on nasal decolonisation was observed already after 2 days of LTX-109 treatment in subjects treated with 2% or 5% LTX-109 compared to vehicle (P≤0.0012, Dunnett's test). No safety issues were noted during the 9-week follow-up period. Minimal reversible epithelial lesions were observed in the nasal cavity. The systemic exposure was very low with a Cmax 1-2 h post dosing (3.72-11.7 ng/mL). One week after treatment initiation LTX-109 was not detectable in any subject. Summary: Intranasal treatment of S. aureus with LTX-109 is safe and reduces the bacterial load already after a single day of treatment. Hence, LTX-109 has the potential as a new and effective antimicrobial agent with low propensity of resistance development that can prevent infections by MSSA/MRSA during hospitalization. ClinicalTrials.gov: NCT01158235. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Antimicrobial Agents and Chemotherapy
volume
59
issue
1
pages
145 - 151
publisher
American Society for Microbiology
external identifiers
  • pmid:25331699
  • wos:000348609500017
  • scopus:84920130753
ISSN
1098-6596
DOI
10.1128/AAC.03513-14
language
English
LU publication?
yes
id
bfbed2cb-a265-4c89-9e59-1bfd96e342c0 (old id 4733695)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25331699?dopt=Abstract
date added to LUP
2014-11-09 23:58:08
date last changed
2017-10-29 03:09:24
@article{bfbed2cb-a265-4c89-9e59-1bfd96e342c0,
  abstract     = {Nasal decolonisation has a proven effect on the prevention of severe Staphylococcus aureus infections and in the control of methicillin resistant S. aureus (MRSA). However, rising rates of resistance to antibiotics highlights the need for new substances for nasal decolonisation. LTX-109 is a broad spectrum, fast-acting bactericidal antimicrobial drug for topical treatment, which causes membrane disruption and cell lysis. This mechanism of action is not associated with cross-resistance and has a low propensity for development of resistance. In the present study persistent nasal MRSA and methicillin sensitive S. aureus carriers were treated for three days with vehicle, 1%, 2% or 5% LTX-109, respectively. A significant effect on nasal decolonisation was observed already after 2 days of LTX-109 treatment in subjects treated with 2% or 5% LTX-109 compared to vehicle (P≤0.0012, Dunnett's test). No safety issues were noted during the 9-week follow-up period. Minimal reversible epithelial lesions were observed in the nasal cavity. The systemic exposure was very low with a Cmax 1-2 h post dosing (3.72-11.7 ng/mL). One week after treatment initiation LTX-109 was not detectable in any subject. Summary: Intranasal treatment of S. aureus with LTX-109 is safe and reduces the bacterial load already after a single day of treatment. Hence, LTX-109 has the potential as a new and effective antimicrobial agent with low propensity of resistance development that can prevent infections by MSSA/MRSA during hospitalization. ClinicalTrials.gov: NCT01158235.},
  author       = {Nilsson, Anna and Janson, Håkan and Wold, Hedda and Fugelli, Anders and Andersson, Karin and Håkangård, Camilla and Olsson, Pernilla and Olsen, Wenche Marie},
  issn         = {1098-6596},
  language     = {eng},
  number       = {1},
  pages        = {145--151},
  publisher    = {American Society for Microbiology},
  series       = {Antimicrobial Agents and Chemotherapy},
  title        = {LTX-109 is a Novel Agent for Nasal Decolonisation of Methicillin Resistant and Sensitive Staphylococcus aureus.},
  url          = {http://dx.doi.org/10.1128/AAC.03513-14},
  volume       = {59},
  year         = {2015},
}